MIAMI, April 22, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Firm”), a supplier of digital therapeutics for the psychedelic and psychological well being sectors, introduced at the moment the Firm is forward of schedule and plans launch its KetaDASH www.ketadash.com ketamine IV remedy by the top of the second quarter. In a February 26, 2021 press launch Ehave introduced plans to launch open testing of its KetaDASH ketamine IV remedy within the second quarter. Ehave has engaged authorized counsel to advise the Firm on the rollout of KetaDASH. Ehave has additionally secured an umbrella coverage to cowl legal responsibility and malpractice insurance coverage on every house supply service. Throughout the subsequent 60 days, KetaDASH plans to start signing up clients and begin referring to native clinics. Ehave is at the moment in negotiations with a number of entities to franchise the KetaDASH platform, or purchase license throughout the US.
The KetaDASH platform permits licensed ketamine clinics and sufferers who’ve been prescribed ketamine by a doctor to manage the therapy at house intravenously. This offers the clinic a possibility to extend revenues by treating sufferers who’re unable to come back to their workplace. KetaDASH will present the platform for medical practitioners to manage Ketamine intravenously to sufferers at house. Ketamine is at the moment used to assist ease ache and permits sedatives to be efficient at decrease doses, lessening the quantity of probably addictive ache remedy required after sure medical procedures. Ketamine is now being studied as a therapy for main melancholy, although it has not but been accredited by the FDA to deal with melancholy.
KetaDASH is a customized psychological care platform designed to immediately join sufferers with extremely expert nurses to supply ketamine remedy at house beneath knowledgeable supervision. The platform has been strategically designed as a wise and intuitive dashboard from the place sufferers and their related nurses can get detailed perception on remedies. The KetaDASH platform will embody software program, staffing, protocols, and tools. Ehave has designed a wise and intuitive dashboard for KetaDASH from the place the purchasers and the related nurses can get detailed perception on how the Ketamine remedy is working. Sufferers will have the ability to create a profile, verify availability of administering nurses, and schedule appointments.
KetaDASH has an settlement in place with Vein-Eye Carry to make use of its infrared imaging expertise. On a regular basis there are 30 million to 40 million vein punctures worldwide and roughly 3 million within the USA. Delays in therapy can happen in roughly 25 % of all sufferers because of the incapacity to ascertain IV entry, or “discover a vein,” as it’s extra generally referred to. One in three makes an attempt to ascertain IV entry end in failure in adults, and one in two makes an attempt fail in pediatrics. With critically in poor health sufferers the failure charge of vein punctures ranges from 10% to 40% the place vein punctures are tougher.
“Ahead considering Know-how goes to be the following wave of how we obtain healthcare,” mentioned Alfred Farrington II, Chief Data Officer of Ehave. Mr. Farrington continued, “The following wave of healthcare innovation is the evolution of ecosystems. KetaDASH has the flexibility to alter the lives of these affected by psychological well being points.”
Ehave Chief Govt Officer, Ben Kaplan, mentioned, “Our continued dedication and dedication to psychological well being is making KetaDASH a actuality. Many sufferers who want ketamine remedy are homebound. KetaDASH offers us the flexibility to supply ketamine as a psychedelic-assisted remedy for people affected by melancholy, nervousness, PTSD or different psychological or emotional well being challenges. KetaDASH won’t solely present doubtlessly lifesaving Ketamine infusion remedy for the therapy of psychiatric problems, it can additionally present Ehave the chance to construct a income producing platform.”
Extra Ehave Inc. Data
We’re really grateful for the assist of EHVVF shareholders! Please be a part of the dialog on our Ehave supporter’s telegram group at https://t.me/EhaveInc.
The corporate posts essential data and updates by way of weekly movies from the official firm YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.
Please comply with Ehave on Twitter @Ehaveinc1
About Ehave, Inc.
Ehave, Inc. (EHVVF) is a frontrunner of digital therapeutics delivering evidence-based therapeutic interventions to sufferers. Our main focus is on enhancing the usual care in therapeutics to forestall or deal with mind problems or ailments by way of using digital therapeutics, independently or collectively, with drugs, gadgets, and different therapies to optimize affected person care and well being outcomes. Our major product is the Ehave Telemetry Portal, which is a psychological well being informatics platform that permits clinicians to make goal and clever selections by way of knowledge insights. The Ehave Infinity Portal presents a strong machine studying and synthetic intelligence platform with a rising set of superior instruments and purposes developed by Ehave and its main companions. This empowers sufferers, healthcare suppliers, and payers to handle a variety of circumstances by way of prime quality, secure, and efficient data-driven involvement with clever and accessible instruments. Extra data on Ehave may be discovered on the Firm’s web site at: www.ehave.com.
Ahead-Wanting Assertion Disclaimer
This press launch comprises “forward-looking statements” throughout the which means of the Personal
Securities Litigation Reform Act of 1995. Such statements could also be preceded by the phrases
“intends,” “might,” “will,” “plans,” “expects,” “anticipates,” “tasks,” “predicts,” “estimates,” “goals,” “believes,” “hopes,” “potential” or comparable phrases. Ahead-looking statements are primarily based on sure assumptions and are topic to numerous recognized and unknown dangers and uncertainties, a lot of that are past the Firm’s management, and can’t be predicted or quantified and consequently, precise outcomes might differ materially from these expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and outcomes of the Firm’s analysis, manufacturing and different growth efforts; (ii) the Firm’s means to advance its merchandise to efficiently full growth and commercialization; (iii) the manufacturing, growth, commercialization, and market acceptance of the Firm’s merchandise; (iv) the shortage of ample funding to finance the product growth and enterprise operations; (v) aggressive firms and applied sciences throughout the Firm’s business and introduction of competing merchandise; (vi) the Firm’s means to ascertain and keep company collaborations; (vii) lack of key administration personnel; (viii) the scope of safety the Firm is ready to set up and keep for mental property rights masking its merchandise and its means to function its enterprise with out infringing the mental property rights of others; (ix) potential failure to adjust to relevant well being data privateness and safety legal guidelines and different state and federal privateness and safety legal guidelines; and (x) the problem of predicting actions of the USA FDA and its laws. All forward-looking statements included on this press launch are made solely as of the date of this press launch. The Firm assumes no obligation to replace any written or oral forward-looking assertion except required by regulation. Extra detailed details about the Firm and the chance components which will have an effect on the belief of forward-looking statements is contained beneath the heading “Threat Elements” in Ehave, Inc.’s Registration
Assertion on Type F-1 filed with the Securities and Change Fee (SEC) on
September 24, 2015, as amended, which is obtainable on the SEC’s web site, http://www.sec.gov.
Media Inquiries: Gabe Rodriguez
Telephone: (623) 261-9046